Immune checkpoint inhibition is an effective anti-cancer therapeutic approach but has
shown limited efficacy in treating colorectal cancer (CRC) patients. Importantly, immune …

Introduction Colorectal cancer (CRC) is a leading cause of death. For three decades,
chemotherapy with or without targeted therapy (provided before or after tumor resection …

Background Colorectal cancer (CRC) is the second leading cause of cancer-related death.
Immunotherapy is one of the new options for cancer treatment. This study aimed to develop …

Colorectal cancer (CRC) is among the top 3 leading causes of cancer-related deaths, and
tumor malignant progression and metastases contribute to the high mortality of advanced …

Tumor-infiltrating immune cells (TIICs) play essential roles in cancer development and
progression. However, the association of TIICs with prognosis in colorectal cancer (CRC) …

Introduction Colorectal cancer (CRC) ranks second for mortality and third for morbidity
among the most commonly diagnosed cancers worldwide. We aimed to investigate the …

Immunotherapy has dramatically changed the landscape of treatment for colorectal cancer
(CRC), but currently lack of effective predictive biomarker, especially for tumors with …

Background Emergence of novel immuno‐therapeutics has shown promising improvement
in the clinical outcome of colorectal cancer (CRC). Objective To identify robust immune …

Colorectal cancer (CRC) is one of the most commonly diagnosed cancers with an estimated
1.8 million new cases worldwide and associated with high mortality rates of 881 000 CRC …

Immune checkpoint inhibitors (ICIs) are monoclonal antibodies that block immune inhibitory
pathways. Administration of ICIs augments T cell-mediated immune responses against …